Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Phase II trial of AP23573 initiated in endometrial cancer patients
August 4th, 2005
Ariad Pharmaceuticals, Inc., (ARIA) announced initiation of enrollment of patients with recurrent or persistent endometrial cancer in a global phase II clinical trial of its novel mTOR inhibitor, AP23573, as a single agent. Endometrial cancer is the most common gynecologic malignancy, including ovarian cancer. This non-randomized study will evaluate the clinical benefit of AP23573 in well-characterized endometrial cancer patients. Up to approximately 45 patients will be enrolled in the trial at several centers in the United States and Europe. AP23573 will be administered intravenously using a daily dosing regimen. Patients will be...
Source: Women's Health Weekly (2005-08-04)
|
